YueXiangYue Health | January 2026 Prospectus Filing Overview
Yellwin
Cardiac Surgery Implantable Medical Device R&D Provider
Highlightll Pharma
Innovative Drug Developer
WeMed
Interventional Medical Device Provider
Westlake Omics
Developer of auxiliary clinical multi-disease diagnostic products
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
In January, the "Spring Festival Gala" of the global biopharmaceutical industry — the 44th J.P. Morgan Healthcare Conference — was grandly held in San Francisco, USA. Investee companies of Everfront Capital, including Jiangsu Ascentage Pharma Development Co., Ltd., GuangZhou GaoLing Pharmaceutical Company, Ltd., AndorMed, Biotron Biotech, and Mylex Biotech, made significant appearances, jointly showcasing the cutting-edge strength of China's innovative pharmaceutical enterprises.
Yifeng's invested companies have also made continuous breakthroughs in key areas such as clinical trials, approvals, and collaborations, outlining a clear trajectory of the industry's accelerating progress and injecting strong momentum into the start of the new year.
01
Progress of Portfolio Companies' IPOs and Financing
NorthX Life
· NorthX Life Plans to List on the STAR Market of the Shanghai Stock Exchange
On January 16, NorthX Life disclosed the prospectus, announcing the start of its issuance. The subscription will take place on January 26, with plans to list on the Shanghai Stock Exchange's STAR Market.
NorthX Life
· NorthX Life Plans to List on the STAR Market of the Shanghai Stock Exchange
On January 16, NorthX Life disclosed the prospectus, announcing the start of its issuance. The subscription will take place on January 26, with plans to list on the Shanghai Stock Exchange's STAR Market.
Yellwin
· Completed Nearly 100 Million Yuan in Series B Financing, Further Strengthening Cardiovascular Surgery Layout
Yellwin
· Completed Nearly 100 Million Yuan in Series B Financing, Further Strengthening Cardiovascular Surgery Layout
Yellwin Announces Completion of Nearly 100 Million Yuan in Equity Financing, Led by EF Capital with Participation from Beishang Capital and Bohai Chuangfu
Yellwin Announces Completion of Nearly 100 Million Yuan in Equity Financing, Led by EF Capital with Participation from Beishang Capital and Bohai Chuangfu
02
Clinical and Commercialization Updates of Invested Companies
GuangZhou GaoLing Pharmaceutical Company,Ltd.
· Interim Analysis of Phase III Clinical Trial of Ginocitib (TLL-018) for Chronic Spontaneous Urticaria (CSU) Meets Primary Endpoint
GuangZhou GaoLing Pharmaceutical Company,Ltd.
· Interim Analysis of Phase III Clinical Trial of Ginocitib (TLL-018) for Chronic Spontaneous Urticaria (CSU) Meets Primary Endpoint
Recently, GaoGuang Pharmaceutical announced that the Phase III clinical trial of its self-developed oral small molecule JAK1/TYK2 inhibitor, Ginocitib, for the treatment of chronic spontaneous urticaria, has achieved positive topline data.
· Brain-penetrant NLRP3 inhibitor HL-400 has completed the single-dose escalation portion of Phase I clinical research.
Recently, GaoGuang Pharmaceutical announced that its self-developed brain-penetrating NLRP3 inhibitor HL-400 has successfully completed the single-dose escalation portion of its Phase I clinical trial plan in healthy volunteers in the United States.
Recently, GaoGuang Pharmaceutical announced that the Phase III clinical trial of its self-developed oral small molecule JAK1/TYK2 inhibitor, Ginocitib, for the treatment of chronic spontaneous urticaria, has achieved positive topline data.
· Brain-penetrant NLRP3 inhibitor HL-400 has completed the single-dose escalation portion of Phase I clinical research.
Recently, GaoGuang Pharmaceutical announced that its self-developed brain-penetrating NLRP3 inhibitor HL-400 has successfully completed the single-dose escalation portion of its Phase I clinical trial plan in healthy volunteers in the United States.
Yinnuo Pharma
· Attend the 2026 China FIC Innovation and Collaboration Summit to Showcase China's Original Strength to the World
Yinnuo Pharma
· Attend the 2026 China FIC Innovation and Collaboration Summit to Showcase China's Original Strength to the World
Recently, the 2026 China FIC Innovation and Collaboration Summit was grandly held during the JP Morgan Healthcare Conference (JPM) in San Francisco, USA. Beijing Yinnuo Medical Technology Co., Ltd. presented its core product, YN001, through a project roadshow at the summit, showcasing China's breakthrough advancements in the field of cardiovascular disease treatment to top global pharmaceutical companies and investment institutions.
Recently, the 2026 China FIC Innovation and Collaboration Summit was grandly held during the JP Morgan Healthcare Conference (JPM) in San Francisco, USA. Beijing Yinnuo Medical Technology Co., Ltd. presented its core product, YN001, through a project roadshow at the summit, showcasing China's breakthrough advancements in the field of cardiovascular disease treatment to top global pharmaceutical companies and investment institutions.
WeMed
· Deeply Involved in the Release Event of the National Medical Service Price Project Guidelines
WeMed
· Deeply Involved in the Release Event of the National Medical Service Price Project Guidelines
On January 20, the National Healthcare Security Administration officially released the "Guidelines for the Establishment of Medical Service Price Projects for Surgical and Treatment Auxiliary Operations (Trial)." WeMed participated in both the exhibition and the live release event as one of the few invited companies.
On January 20, the National Healthcare Security Administration officially released the "Guidelines for the Establishment of Medical Service Price Projects for Surgical and Treatment Auxiliary Operations (Trial)." WeMed participated in both the exhibition and the live release event as one of the few invited companies.
Westlake Omics
· IGF-Ⅰ Clinical Mass Spectrometry Diagnostic Product Receives EU CE Certification
Westlake Omics
· IGF-Ⅰ Clinical Mass Spectrometry Diagnostic Product Receives EU CE Certification
On January 21, Westlake Omics' Insulin-like Growth Factor I (IGF-I) ELISA Kit officially completed the EU CE certification and has been registered in the European Medical Devices Database (EUDAMED), gaining approval to enter the EU market.
On January 21, Westlake Omics' Insulin-like Growth Factor I (IGF-I) ELISA Kit officially completed the EU CE certification and has been registered in the European Medical Devices Database (EUDAMED), gaining approval to enter the EU market.
Century Healthcare
· Postoperative visual acuity (far/middle/near): 1.2/1.0/1.2
Century Healthcare
· Postoperative visual acuity (far/middle/near): 1.2/1.0/1.2
Recently, Professor Zhang Shunhua from the Ophthalmology Department of Peking Union Medical College Hospital successfully performed a bilateral implantation of Century Healthcare's Lightrix® Trifocal Plus intraocular lens for a patient with high visual demands. One day after the surgery, the patient’s far, intermediate, and near vision reached excellent levels of 1.2, 1.0, and 1.2, respectively.
Recently, Professor Zhang Shunhua from the Ophthalmology Department of Peking Union Medical College Hospital successfully performed a bilateral implantation of Century Healthcare's Lightrix® Trifocal Plus intraocular lens for a patient with high visual demands. One day after the surgery, the patient’s far, intermediate, and near vision reached excellent levels of 1.2, 1.0, and 1.2, respectively.
Jingwei Shida
· The First Article in China! Domestically Produced Confocal Technology Aids in the Precise Diagnosis of Pleural Diseases
Jingwei Shida
· The First Article in China! Domestically Produced Confocal Technology Aids in the Precise Diagnosis of Pleural Diseases
Recently, "Frontiers in Oncology》published a prospective research achievement from Wuhan Central Hospital. The BIOPSEE® Beixi® Confocal Microendoscope, produced in China by Jingwei Shida, used in this study has been put into use in more than 600 top hospitals across China.
Recently, "Frontiers in Oncology》published a prospective research achievement from Wuhan Central Hospital. The BIOPSEE® Beixi® Confocal Microendoscope, produced in China by Jingwei Shida, used in this study has been put into use in more than 600 top hospitals across China.
Xuanyu Medical
· Multiple Hospitals Apply XuanYu Medical
Xuanyu Medical
· Multiple Hospitals Apply XuanYu Medical
The Cardiology Department of Zunyi Medical University Affiliated Hospital, Xingtai People's Hospital, Jixi County People's Hospital, and the Cardiovascular Department of Guzhen County People's Hospital successfully applied XuanYu Medical's RhythPulse.®Pulsed Electric Field Ablation Catheter.
The Cardiology Department of Zunyi Medical University Affiliated Hospital, Xingtai People's Hospital, Jixi County People's Hospital, and the Cardiovascular Department of Guzhen County People's Hospital successfully applied XuanYu Medical's RhythPulse.®Pulsed Electric Field Ablation Catheter.
Z众生睿创
· Reached a cooperation agreement with Qilu Pharmaceutical to jointly promote the commercialization of RAY1225 in China.
Z众生睿创
· Reached a cooperation agreement with Qilu Pharmaceutical to jointly promote the commercialization of RAY1225 in China.
On January 16, Zhenzhong Ruichuang and Qilu Pharmaceutical held a strategic cooperation signing ceremony, jointly announcing the signing of a licensing agreement for the innovative drug RAY1225 injection, a super-long-acting agonist targeting GLP-1/GIP dual receptors.
On January 16, Zhenzhong Ruichuang and Qilu Pharmaceutical held a strategic cooperation signing ceremony, jointly announcing the signing of a licensing agreement for the innovative drug RAY1225 injection, a super-long-acting agonist targeting GLP-1/GIP dual receptors.
· RAY1225 Injection Monotherapy for Type 2 Diabetes Completes Phase III Clinical Enrollment Target Efficiently
Recently, the Phase III clinical trial of RAY1225 Injection by Zhongsheng Ruichuang has efficiently completed the enrollment target for monotherapy in type 2 diabetes.
Recently, the Phase III clinical trial of RAY1225 Injection by Zhongsheng Ruichuang has efficiently completed the enrollment target for monotherapy in type 2 diabetes.
Harbour BioMed
· Acquisition of Spruce Biosciences Common Stock Deepens Strategic Cooperation Between Both Parties
Harbour BioMed
· Acquisition of Spruce Biosciences Common Stock Deepens Strategic Cooperation Between Both Parties
Recently, Harbour BioMed announced that it has exercised its warrants through its wholly-owned subsidiary to acquire common shares of Spruce Biosciences, Inc. After the completion of the transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares and about 3.1% of the fully diluted shares of Spruce.
Recently, Harbour BioMed announced that it has exercised its warrants through its wholly-owned subsidiary to acquire common shares of Spruce Biosciences, Inc. After the completion of the transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares and about 3.1% of the fully diluted shares of Spruce.
· Proposes to Repurchase Company Shares for No More Than HKD 300 Million
Recently, Harbour BioMed announced that the company has decided to exercise its repurchase authorization and will repurchase shares on the open market from time to time depending on market conditions, using up to HKD 300 million for the proposed share repurchase. Additionally, the company may conduct further repurchases within the applicable authorization based on market conditions.
· Proposes to Repurchase Company Shares for No More Than HKD 300 Million
Recently, Harbour BioMed announced that the company has decided to exercise its repurchase authorization and will repurchase shares on the open market from time to time depending on market conditions, using up to HKD 300 million for the proposed share repurchase. Additionally, the company may conduct further repurchases within the applicable authorization based on market conditions.
Innovo
· Endoscopic Ultrasound Deployment
Innovo
· Endoscopic Ultrasound Deployment
Recently, the WeMed miniature probe endoscopic ultrasound system has been officially introduced to the Pediatrics Department of the First Affiliated Hospital of Guangzhou Medical University, as well as to the First People's Hospital of Urumqi (Children's Hospital), the Sixth Affiliated Hospital of Xinjiang Medical University, and the Seventh Division Hospital of the Xinjiang Production and Construction Corps.
Recently, the WeMed miniature probe endoscopic ultrasound system has been officially introduced to the Pediatrics Department of the First Affiliated Hospital of Guangzhou Medical University, as well as to the First People's Hospital of Urumqi (Children's Hospital), the Sixth Affiliated Hospital of Xinjiang Medical University, and the Seventh Division Hospital of the Xinjiang Production and Construction Corps.
Jiangsu Ascentage Pharma Development Co., Ltd.
· Attended the 44th Annual J.P. Morgan Healthcare Conference and Delivered a Corporate Presentation
Jiangsu Ascentage Pharma Development Co., Ltd.
· Attended the 44th Annual J.P. Morgan Healthcare Conference and Delivered a Corporate Presentation
Recently, Ascentage Pharma announced that Dr. Dajun Yang, Chairman and CEO of the company, has been invited to speak at the 44th Annual J.P. Morgan Healthcare Conference, showcasing the company's achievements and future prospects under its patient-centered global innovation strategy.
Recently, Ascentage Pharma announced that Dr. Dajun Yang, Chairman and CEO of the company, has been invited to speak at the 44th Annual J.P. Morgan Healthcare Conference, showcasing the company's achievements and future prospects under its patient-centered global innovation strategy.
Quanxin Bio
· QX030N Completes First Dosing of Phase I Clinical Trial Subjects
Quanxin Bio
· QX030N Completes First Dosing of Phase I Clinical Trial Subjects
Recently, Quanxin Biotech announced that the first batch of healthy volunteers have been successfully dosed in the Phase I clinical trial of QX030N/CLD-423 (Caldera's R&D code), which was jointly developed with its partner Caldera.
Recently, Quanxin Biotech announced that the first batch of healthy volunteers have been successfully dosed in the Phase I clinical trial of QX030N/CLD-423 (Caldera's R&D code), which was jointly developed with its partner Caldera.
AsiaPharm
· APL-2401 Phase I Clinical Trial in Patients with FGFR2/3-Driven Advanced Solid Tumors Completes First Patient Enrollment in China
AsiaPharm
· APL-2401 Phase I Clinical Trial in Patients with FGFR2/3-Driven Advanced Solid Tumors Completes First Patient Enrollment in China
On January 8, Ascentage Pharma announced that the first patient has been enrolled in China for the Phase I clinical trial of its self-developed APL-2401 (drug name: ASN-8639 tablets) in patients with advanced solid tumors driven by FGFR2/3.
On January 8, Ascentage Pharma announced that the first patient has been enrolled in China for the Phase I clinical trial of its self-developed APL-2401 (drug name: ASN-8639 tablets) in patients with advanced solid tumors driven by FGFR2/3.
Frontier Biologics
· Notice of Acceptance for Clinical Trial Application of FB7013, a Drug Registered for Production in China
Frontier Biologics
· Notice of Acceptance for Clinical Trial Application of FB7013, a Drug Registered for Production in China
Recently, Frontier Biotech submitted a clinical trial application to the National Medical Products Administration for an siRNA drug targeting the key protein MASP-2 in the lectin pathway of the complement system, which was independently developed by the company.
Recently, Frontier Biotech submitted a clinical trial application to the National Medical Products Administration for an siRNA drug targeting the key protein MASP-2 in the lectin pathway of the complement system, which was independently developed by the company.
03
Approval Status of New Drugs and Devices from Invested Companies
Core Medical
· China's First PVAD Approved for Marketing by NMPA
Core Medical
· China's First PVAD Approved for Marketing by NMPA
Recently, NMPA announced the approval of Core Medical's interventional left ventricular assist device and the interventional left ventricular assist catheter pump kit APL-1202, which received approval under Health Canada’s Special Access Program.
Recently, NMPA announced the approval of Core Medical's interventional left ventricular assist device and the interventional left ventricular assist catheter pump kit APL-1202, which received approval under Health Canada’s Special Access Program.
KONING BIO
· P002, a First-in-Class Dry Eye Syndrome Therapy, Receives Clinical Trial Approval from Health Canada
KONING BIO
· P002, a First-in-Class Dry Eye Syndrome Therapy, Receives Clinical Trial Approval from Health Canada
Recently, CONE Bio announced that its dry eye syndrome eye drop P002 has been approved by Health Canada for the First-in-Human (FIH) clinical study.
Recently, CONE Bio announced that its dry eye syndrome eye drop P002 has been approved by Health Canada for the First-in-Human (FIH) clinical study.
Century Healthcare
· New Model of Next-Generation Fully Hydrophobic Intraocular Lens Approved for Marketing
Century Healthcare
· New Model of Next-Generation Fully Hydrophobic Intraocular Lens Approved for Marketing
Recently, Tianjin Century Healthcare's "New Generation All-Around Hydrophobic Intraocular Lens" with the new model ASOB55LPS has officially received approval from the National Medical Products Administration (NMPA) for market launch and is expected to be put into clinical use starting from February this year.
Recently, Tianjin Century Healthcare's "New Generation All-Around Hydrophobic Intraocular Lens" with the new model ASOB55LPS has officially received approval from the National Medical Products Administration (NMPA) for market launch and is expected to be put into clinical use starting from February this year.
Jiangsu Ascentage Pharma Development Co., Ltd.
· BTK Degrader APG-3288 Receives FDA IND Approval in the United States
Jiangsu Ascentage Pharma Development Co., Ltd.
· BTK Degrader APG-3288 Receives FDA IND Approval in the United States
Recently, Ascentage Pharma announced that the IND application for its original next-generation BTK-targeted protein degrader APG-3288 has been approved by the U.S. FDA.
Recently, Ascentage Pharma announced that the IND application for its original next-generation BTK-targeted protein degrader APG-3288 has been approved by the U.S. FDA.
AsiaPharm
· APL-1202 Granted Special Access Approval by Health Canada
Recently, Ascentage Pharma announced that its self-developed drug APL-1202 (Nitrhydroxyquinoline Tablets) has been approved by Health Canada under the Special Access Program.
AsiaPharm
· APL-1202 Granted Special Access Approval by Health Canada
Recently, Ascentage Pharma announced that its self-developed drug APL-1202 (Nitrhydroxyquinoline Tablets) has been approved by Health Canada under the Special Access Program.
· APL-2401 Phase I Clinical Trial Application Approved by NMPA for Patients with FGFR2/3-Driven Advanced Solid Tumors
On January 22, Ascentage Pharma announced that APL-2401 (drug name: ASN-8639 tablets) had received ethical approval from the Australian Human Research Ethics Committee for a Phase I clinical trial in patients with advanced solid tumors driven by FGFR2/3. The clinical trial has also been registered with the Therapeutic Goods Administration (TGA), which is part of the Australian Department of Health.
· APL-2401 Phase I Clinical Trial Application Approved by NMPA for Patients with FGFR2/3-Driven Advanced Solid Tumors
On January 22, Ascentage Pharma announced that APL-2401 (drug name: ASN-8639 tablets) had received ethical approval from the Australian Human Research Ethics Committee for a Phase I clinical trial in patients with advanced solid tumors driven by FGFR2/3. The clinical trial has also been registered with the Therapeutic Goods Administration (TGA), which is part of the Australian Department of Health.
Harbour BioMed
· National Science and Technology Innovation Major Project Approved for Establishment
Harbour BioMed
· National Science and Technology Innovation Major Project Approved for Establishment
Recently, the project "Research on the Pathogenesis of Pancreatic Cancer and New Paradigms for Clinical Precision Diagnosis and Treatment," led by Shanghai Changhai Hospital and jointly applied for with Harbour BioMed, has been successfully approved for立项.
Recently, the project "Research on the Pathogenesis of Pancreatic Cancer and New Paradigms for Clinical Precision Diagnosis and Treatment," led by Shanghai Changhai Hospital and jointly applied for with Harbour BioMed, has been successfully approved for立项.
3D Medicines
· The world's first and only approved subcutaneous injection PD-L1 inhibitor
3D Medicines
· The world's first and only approved subcutaneous injection PD-L1 inhibitor
On January 9, 3D Medicines announced that the National Medical Products Administration (NMPA) has officially accepted the New Drug Application (NDA) for its commercial product Envada® in combination with gemcitabine and oxaliplatin for the first-line treatment of unresectable or metastatic biliary tract cancer.
On January 9, 3D Medicines announced that the National Medical Products Administration (NMPA) has officially accepted the New Drug Application (NDA) for its commercial product Envada® in combination with gemcitabine and oxaliplatin for the first-line treatment of unresectable or metastatic biliary tract cancer.
04
Honors of Invested Enterprises
04
Honors of Invested Enterprises
Awarded the "2025 Annual Outstanding Sci-Tech Innovation Enterprise Award" by the Xuhui District Government of Shanghai
· HARMONY
Awarded the "2025 Annual Outstanding Sci-Tech Innovation Enterprise Award" by the Xuhui District Government of Shanghai
· HARMONY
Selected for the 2026 American Association for Cancer Research Annual Meeting
· Tiangang Med-Inno - Two Innovative Research Achievements
Selected for the 2026 American Association for Cancer Research Annual Meeting
· Tiangang Med-Inno - Two Innovative Research Achievements
Passed the re-examination of Shenzhen's "Specialized, Refined, Unique, and Innovative Small and Medium-sized Enterprises"
· Zifu Medical
Passed the re-examination of Shenzhen's "Specialized, Refined, Unique, and Innovative Small and Medium-sized Enterprises"
· Zifu Medical
AwardedFirst Prize of Natural Science Award at the 2026 Hubei Provincial Science and Technology Innovation Conference
· Huiguan Bio-3D Pathology Core Technology
AwardedFirst Prize of Natural Science Award at the 2026 Hubei Provincial Science and Technology Innovation Conference
· Huiguan Bio-3D Pathology Core Technology
AwardediiMedia Ranking - Top 40 Leading Enterprises in China's Innovative Drug Export Industry 2025
· Jiangsu Ascentage Pharma Development Co., Ltd., 3D Medicines, and HARBOR BioMed
AwardediiMedia Ranking - Top 40 Leading Enterprises in China's Innovative Drug Export Industry 2025
· Jiangsu Ascentage Pharma Development Co., Ltd., 3D Medicines, and HARBOR BioMed
Awarded the "National High-tech Enterprise" Certification
· Xuanyu Medical
Awarded the "National High-tech Enterprise" Certification
· Xuanyu Medical
Shortlisted for the 2025 AI Medical Device Innovation Task "Challenge Leader" List by the Ministry of Industry and Information Technology and the National Medical Products Administration
· Pumen Technology
Shortlisted for the 2025 AI Medical Device Innovation Task "Challenge Leader" List by the Ministry of Industry and Information Technology and the National Medical Products Administration
· Pumen Technology
Ranked on the Jiangsu Unicorn Enterprise List
· Bioinno
Ranked on the Jiangsu Unicorn Enterprise List
· Bioinno
Awarded"Satisfactory Result of the 2025 Proficiency Testing for Bevacizumab Concentration in Monkey Serum"
· Tianqin Bio - Vazumab Testing Capability
Awarded"Satisfactory Result of the 2025 Proficiency Testing for Bevacizumab Concentration in Monkey Serum"
· Tianqin Bio - Vazumab Testing Capability
AgainExcerpt from the Guangdong Provincial Department of Industry and Information Technology - Guangdong Province Manufacturing Single Champion Enterprises
· NorthX Life
05
Yifeng Honor
▷ Integration in China
Yifeng Capital-
Top 100 Venture Capital Institutions in China for 2025
Zhu Pai-
Outstanding Chinese Investor of 2025
▷ LP CLUB
Yifeng Capital-
Top 20 Best Medical Device Investment Institutions in 2025
Zhu Pai-
Top 30 Biomedical Investors of 2025
2025 Private Equity Investment Opinion Leader
▷ Investor Network
Edge Capital-
Top 35 Best Investment Institutions in the Healthcare Sector for 2025
Top 50 Best Venture Capital Institutions in 2025
Zhu Pai-
Top 10 Best Investors in the Healthcare Sector for 2025
▷ Enterprise Business Card
Yifeng Capital-
TOP 50 Most Active Venture Capital Institutions in China 2025
Zhu Pai-
Top 100 Best Investors & Financial Advisors in China for 2025
▷ IPO Early Insights
Efung Capital-
Top 100 Best Investment Institutions in IPO 2025
Best Healthcare Investment Institution
▷ China Venture Capital Research Institute
Yifeng Capital-
Top 30 VC Investment Institutions Most Favored by LPs in China for 2025
▷ Titanium Media Venture Capitalist
Efung Capital-
Top 20 in the Healthcare Sector of the 2025 Pioneer List
06
Yifeng Chronicle
Yifeng Capital's Zhu Pai Attends JPM in the U.S.
· January 12，The 44th J.P. Morgan Healthcare Conference was grandly held in San Francisco, USA.Yifeng Capital CEO Zhu Pai Attends JPM Conference in the U.S. — This Marks Yifeng Capital's Fourth Participation in the JPM Conference, Exploring Industry Trends and Uncovering Collaboration Opportunities with Global Leaders in Innovative Pharmaceuticals and Senior Investors, While Showcasing to the World "The Potential and Value of Healthcare Investment in China."
AgainExcerpt from the Guangdong Provincial Department of Industry and Information Technology - Guangdong Province Manufacturing Single Champion Enterprises
· NorthX Life
05
Yifeng Honor
▷ Integration in China
Yifeng Capital-
Top 100 Venture Capital Institutions in China for 2025
Zhu Pai-
Outstanding Chinese Investor of 2025
▷ LP CLUB
Yifeng Capital-
Top 20 Best Medical Device Investment Institutions in 2025
Zhu Pai-
Top 30 Biomedical Investors of 2025
2025 Private Equity Investment Opinion Leader
▷ Investor Network
Edge Capital-
Top 35 Best Investment Institutions in the Healthcare Sector for 2025
Top 50 Best Venture Capital Institutions in 2025
Zhu Pai-
Top 10 Best Investors in the Healthcare Sector for 2025
▷ Enterprise Business Card
Yifeng Capital-
Zhu Pai-
Top 100 Best Investors & Financial Advisors in China for 2025
▷ IPO Early Insights
Efung Capital-
Top 100 Best Investment Institutions in IPO 2025
Best Healthcare Investment Institution
▷ China Venture Capital Research Institute
Yifeng Capital-
Top 30 VC Investment Institutions Most Favored by LPs in China for 2025
▷ Titanium Media Venture Capitalist
Efung Capital-
Top 20 in the Healthcare Sector of the 2025 Pioneer List
06
Yifeng Chronicle
Yifeng Capital's Zhu Pai Attends JPM in the U.S.
· January 12，The 44th J.P. Morgan Healthcare Conference was grandly held in San Francisco, USA.Yifeng Capital CEO Zhu Pai Attends JPM Conference in the U.S. — This Marks Yifeng Capital's Fourth Participation in the JPM Conference, Exploring Industry Trends and Uncovering Collaboration Opportunities with Global Leaders in Innovative Pharmaceuticals and Senior Investors, While Showcasing to the World "The Potential and Value of Healthcare Investment in China."
Efung Capital2026 Flag Football Team Building Event Successfully Concluded
· On January 29, the 2026 Yifeng Capital annual team-building event "Yifeng's Direction, Dare to Venture, Flag Football Challenge" successfully concluded. During the event, participants demonstrated another level of team integration through sprints and collaboration, while also witnessing each other's efforts and默契.
Efung Capital2026 Flag Football Team Building Event Successfully Concluded
· On January 29, the 2026 Yifeng Capital annual team-building event "Yifeng's Direction, Dare to Venture, Flag Football Challenge" successfully concluded. During the event, participants demonstrated another level of team integration through sprints and collaboration, while also witnessing each other's efforts and默契.